CN103121992A - 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法 - Google Patents
制备用于制备艾美拉唑钠盐的结晶修饰物的新方法 Download PDFInfo
- Publication number
- CN103121992A CN103121992A CN2013100244957A CN201310024495A CN103121992A CN 103121992 A CN103121992 A CN 103121992A CN 2013100244957 A CN2013100244957 A CN 2013100244957A CN 201310024495 A CN201310024495 A CN 201310024495A CN 103121992 A CN103121992 A CN 103121992A
- Authority
- CN
- China
- Prior art keywords
- sodium salt
- preparation
- esomeprazole
- esomeprazole sodium
- crystal modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 239000013078 crystal Substances 0.000 title abstract description 63
- 230000004048 modification Effects 0.000 title abstract description 49
- 238000012986 modification Methods 0.000 title abstract description 49
- 238000000034 method Methods 0.000 title abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 22
- 230000008569 process Effects 0.000 title abstract description 6
- 239000003607 modifier Substances 0.000 claims description 25
- 238000010586 diagram Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 31
- 239000002904 solvent Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 238000001035 drying Methods 0.000 description 12
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000008025 crystallization Effects 0.000 description 10
- 229960004770 esomeprazole Drugs 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229960000381 omeprazole Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 238000002050 diffraction method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- FOFFPEFVSRGLOZ-JIDHJSLPSA-N potassium;5-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [K+].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C FOFFPEFVSRGLOZ-JIDHJSLPSA-N 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960000496 esomeprazole sodium Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 201000000052 gastrinoma Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- MQEUGMWHWPYFDD-JIDHJSLPSA-N magnesium;6-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical group [Mg].C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C MQEUGMWHWPYFDD-JIDHJSLPSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013864 duodenitis Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58261704P | 2004-06-24 | 2004-06-24 | |
| US60/582617 | 2004-06-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800208742A Division CN1972928A (zh) | 2004-06-24 | 2005-06-20 | 制备用于制备依美拉唑钠盐的结晶修饰物的新方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103121992A true CN103121992A (zh) | 2013-05-29 |
Family
ID=35782078
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100244957A Pending CN103121992A (zh) | 2004-06-24 | 2005-06-20 | 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法 |
| CN201410063477.4A Pending CN103772360A (zh) | 2004-06-24 | 2005-06-20 | 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法 |
| CNA2005800208742A Pending CN1972928A (zh) | 2004-06-24 | 2005-06-20 | 制备用于制备依美拉唑钠盐的结晶修饰物的新方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410063477.4A Pending CN103772360A (zh) | 2004-06-24 | 2005-06-20 | 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法 |
| CNA2005800208742A Pending CN1972928A (zh) | 2004-06-24 | 2005-06-20 | 制备用于制备依美拉唑钠盐的结晶修饰物的新方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8658799B2 (enExample) |
| EP (1) | EP1765806A1 (enExample) |
| JP (2) | JP5457632B2 (enExample) |
| KR (2) | KR20130140918A (enExample) |
| CN (3) | CN103121992A (enExample) |
| AU (1) | AU2005257709C1 (enExample) |
| BR (1) | BRPI0512522A (enExample) |
| CA (1) | CA2570795C (enExample) |
| HK (1) | HK1197065A1 (enExample) |
| MX (1) | MXPA06015031A (enExample) |
| NZ (1) | NZ551970A (enExample) |
| WO (1) | WO2006001753A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104031032A (zh) * | 2014-07-04 | 2014-09-10 | 江苏奥赛康药业股份有限公司 | 一种埃索美拉唑钠化合物及其药物组合物 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1907375B1 (en) * | 2005-06-08 | 2013-07-24 | LEK Pharmaceuticals d.d. | Crystalline solvate of omeprazole sodium |
| WO2007055178A1 (ja) * | 2005-11-08 | 2007-05-18 | Japan Health Sciences Foundation | 細胞の分取方法、及び当該方法に用いる基材 |
| US8063074B2 (en) | 2006-05-04 | 2011-11-22 | Dr. Reddy's Laboratories Limited | Polymorphic forms of esomeprazole sodium |
| EP2143722A1 (en) | 2008-07-09 | 2010-01-13 | Lek Pharmaceuticals D.D. | Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium |
| MX2012009220A (es) | 2010-02-12 | 2012-09-07 | Esteve Quimica Sa | Procedimiento de preparacion de la sal sodica de esomeprazol. |
| CN102746272B (zh) * | 2012-04-11 | 2014-06-25 | 江苏奥赛康药业股份有限公司 | 一种埃索美拉唑钠多晶型物及其制备方法和应用 |
| CN102746273A (zh) * | 2012-05-29 | 2012-10-24 | 江苏奥赛康药业股份有限公司 | 一种埃索美拉唑钠多晶型物及其在注射用药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4378974A (en) | 1982-06-09 | 1983-04-05 | Allis-Chalmers Corporation | Start-up method for coal gasification plant |
| SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| NZ244301A (en) * | 1991-09-20 | 1994-08-26 | Merck & Co Inc | Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds |
| US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| WO1995032957A1 (en) * | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles |
| SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| SE510666C2 (sv) * | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| SE510643C2 (sv) * | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
| NL1007699C2 (nl) | 1997-12-04 | 1999-06-09 | Medisize Bv | Beademingssysteem. |
| SE9900274D0 (sv) * | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
| EP1206466B1 (en) * | 1999-08-26 | 2005-10-12 | aaiPharma Inc. | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| AU2001276721A1 (en) | 2000-08-04 | 2002-02-18 | Takeda Chemical Industries Ltd. | Salts of benzimidazole compound and use thereof |
| WO2003089408A2 (en) | 2002-04-22 | 2003-10-30 | Sun Pharmaceutical Industries Limited | Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts |
| WO2004002982A2 (en) | 2002-06-27 | 2004-01-08 | Dr. Reddy's Laboratories Limited | A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof |
| EA200500673A1 (ru) | 2002-10-22 | 2005-12-29 | Рэнбакси Лабораториз Лимитед | Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе |
| DK1578742T3 (da) * | 2002-12-06 | 2013-01-21 | Nycomed Gmbh | Fremgangsmåde til fremstilling af optisk rene aktive forbindelser |
| AU2003238671A1 (en) | 2003-04-10 | 2004-11-01 | Hetero Drugs Limitd | Novel crystalline forms of s-omeprazole magnesium |
| MXPA05013316A (es) | 2003-06-10 | 2006-03-17 | Teva Pharma | Proceso para preparar bencimidazoles 2[-(piridinil)metil]sulfinil-sustituidos y derivados clorados novedosos de pantoprazol. |
-
2005
- 2005-06-20 BR BRPI0512522-7A patent/BRPI0512522A/pt not_active IP Right Cessation
- 2005-06-20 CN CN2013100244957A patent/CN103121992A/zh active Pending
- 2005-06-20 AU AU2005257709A patent/AU2005257709C1/en not_active Ceased
- 2005-06-20 CA CA2570795A patent/CA2570795C/en not_active Expired - Fee Related
- 2005-06-20 JP JP2007518003A patent/JP5457632B2/ja not_active Expired - Fee Related
- 2005-06-20 MX MXPA06015031A patent/MXPA06015031A/es active IP Right Grant
- 2005-06-20 US US11/570,717 patent/US8658799B2/en not_active Expired - Fee Related
- 2005-06-20 KR KR1020137032748A patent/KR20130140918A/ko not_active Ceased
- 2005-06-20 CN CN201410063477.4A patent/CN103772360A/zh active Pending
- 2005-06-20 WO PCT/SE2005/000954 patent/WO2006001753A1/en not_active Ceased
- 2005-06-20 KR KR1020137005546A patent/KR20130038949A/ko not_active Withdrawn
- 2005-06-20 NZ NZ551970A patent/NZ551970A/en not_active IP Right Cessation
- 2005-06-20 EP EP05754053A patent/EP1765806A1/en not_active Ceased
- 2005-06-20 CN CNA2005800208742A patent/CN1972928A/zh active Pending
-
2012
- 2012-09-18 JP JP2012203798A patent/JP2012246316A/ja active Pending
-
2014
- 2014-10-23 HK HK14110572.9A patent/HK1197065A1/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104031032A (zh) * | 2014-07-04 | 2014-09-10 | 江苏奥赛康药业股份有限公司 | 一种埃索美拉唑钠化合物及其药物组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06015031A (es) | 2007-02-08 |
| US8658799B2 (en) | 2014-02-25 |
| JP2012246316A (ja) | 2012-12-13 |
| CN1972928A (zh) | 2007-05-30 |
| JP2008503574A (ja) | 2008-02-07 |
| AU2005257709A1 (en) | 2006-01-05 |
| KR20130038949A (ko) | 2013-04-18 |
| AU2005257709B2 (en) | 2008-11-13 |
| CA2570795A1 (en) | 2006-01-05 |
| AU2005257709C1 (en) | 2011-02-24 |
| US20080039503A1 (en) | 2008-02-14 |
| BRPI0512522A (pt) | 2008-03-11 |
| KR20130140918A (ko) | 2013-12-24 |
| NZ551970A (en) | 2010-01-29 |
| HK1197065A1 (en) | 2015-01-02 |
| WO2006001753A1 (en) | 2006-01-05 |
| JP5457632B2 (ja) | 2014-04-02 |
| CN103772360A (zh) | 2014-05-07 |
| EP1765806A1 (en) | 2007-03-28 |
| CA2570795C (en) | 2013-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002501529A (ja) | Ｓ−オメプラゾールの新規な形態 | |
| NZ336024A (en) | Neutral crystalline S-omeprazole | |
| NO320014B1 (no) | Ny krystallinsk form for omeprazol, fremgangsmate for fremstilling derav, omeprazolsammensetning, farmasoytisk formulering samt anvendelse av omeprazolformen. | |
| JP2012246316A (ja) | エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法 | |
| US20120122933A1 (en) | Compounds | |
| JP2005521693A (ja) | オメプラゾール及びエソメプラゾールのアルキルアンモニウム塩 | |
| US7560472B2 (en) | Salts of omeprazole and esomeprazole II | |
| US7326724B2 (en) | Salts of omeprazole and esomeprazole I | |
| KR20240171566A (ko) | 테고프라잔의 신규한 공동무정형 및 이를 포함하는 약학 조성물 | |
| US8124779B2 (en) | Process for the preparation of esomeprazole non-salt form | |
| KR20070023757A (ko) | 에소메프라졸 나트륨염의 제조에서 사용하기 위한 결정변형의 제조를 위한 신규한 방법 | |
| HK1184464A (en) | New process for preparation of crystal modifications for use in preparation of esomeprazole sodium salt | |
| MX2008006935A (en) | New process for the preparation of esomeprazole non-salt form | |
| JPH01121272A (ja) | ベンズイミダゾール誘導体の多形体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1184464 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130529 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1184464 Country of ref document: HK |